Lior Alkalay

Lior Alkalay

InvestorPlace Contributor

Lior is a consummate professional; a passionate analyst and economist with comprehensive experience within the financial services sector. With nearly 10 years of experience in trading and investment, Lior has provided his clients with crisp, clear and thorough analysis. Before becoming an independent analyst, he was employed for several years as the director of sell-side research at a leading international broker.

Lior specializes in mid- to long-range stock and ETF analyses using an out-of-the-box investment approach. That approach includes top-down analysis to identify the most attractive sectors, and then he balances it with cherry-picking to find the best opportunities.

Recent Articles

iPhone is a Double Edged Sword for AAPL Stock

By Lior Alkalay, InvestorPlace Contributor

With iPhone revenue being the lion's share of Apple earnings, the company is putting itself in a risky position.

How to Play Cybersecurity Stocks Without Getting Burned

By Lior Alkalay, InvestorPlace Contributor

Cybersecurity stocks are valued at a large premium to their results but present a lot of promise. Is there a way to reduce downside risk?

The GLD ETF Will Shine as China Play Dims

By Lior Alkalay, InvestorPlace Contributor

The GLD ETF tanked as Chinese investors sold gold and bought stocks. Now as the Chinese stock market moves south, this trend may reverse.

Here’s Why It’s Time To Short Twitter Stock

By Lior Alkalay, InvestorPlace Contributor

Twitter stock is under pressure.With the company spending most of its income on R&D, investors are impatient and could push TWTR even lower.

Fast-Food Showdown: YUM Stock vs. MCD Stock

By Lior Alkalay, InvestorPlace Contributor

Investors in 2015 have loved Yum Brands and soured on McDonald's. But YUM stock's valuations are getting steep, and MCD is getting an infusion of new blood.

Pimco’s BOND ETF Has an Edge

By Lior Alkalay, InvestorPlace Contributor

As the Fed prepares to raise rates, investors are terrified of bonds. With funds like Pimco's BOND ETF, they shouldn't be.

Will the CVS Health-Target Deal Actually Help CVS Stock?

By Lior Alkalay, InvestorPlace Contributor

While Wall Street didn't exactly cheer CVS' buyout of Target's pharmacy business, CVS stock holders will be rewarded soon enough.

SHAK: Should You Flip Shake Shack Stock?

By Lior Alkalay, InvestorPlace Contributor

Shake Shack stock is a hit with consumers, but it's terribly overpriced for a company that's having a difficult time generating meaningful profits.

Load More